Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC.
基于淋巴细胞亚群的非侵入性生物标志物可预测 EGFR-TKI 预处理的 EGFR 突变型 NSCLC 的免疫化疗疗效
期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2025.113211
Song Lianxi, Zeng Liang, Xu Qinqin, Li Yizhi, Guo Wenhuan, Lin Shaoding, Jiang Wenjuan, Wang Zhan, Deng Li, Huang Zhe, Qin Haoyue, Yan Huan, Zhang Xing, Tong Fan, Zhang Ruiguang, Liu Zhaoyi, Zhang Lin, Yu Juan, Yang Xue, Xia Yang, Dong Xiaorong, Zhang Gao, Yang Nong, Zhang Yongchang